Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | HTR1F | P30939 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 2/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21251097 | 0.82 | PIK3CD (0.43) | PIK3CDHTR1AHTR1BHTR1FCYP1A2 | |
| SCHEMBL22358032 | 0.82 | HDAC8 (0.38) | HDAC8GPR119HTR1AHTR1BHTR1F | |
| SCHEMBL19689422 | 0.81 | PIK3CD (0.43) | PIK3CDHTR1AHTR1BHTR1FLRRK2 | |
| SCHEMBL19697958 | 0.79 | PIK3CD (0.42) | PIK3CDHTR1AHTR1BHTR1FLRRK2 | |
| SCHEMBL17303550 | 0.77 | HTR1A (0.52) | HDAC8GPR119HTR1AHTR1BHTR1F | |
| SCHEMBL17304006 | 0.75 | HTR1A (0.45) | HDAC8GPR119HTR1AHTR1BHTR1F | |
| SCHEMBL16417640 | 0.75 | HTR2C (0.39) | HDAC8GPR119 | |
| SCHEMBL19700132 | 0.73 | HTR1A (0.45) | PIK3CDHDAC8GPR119HTR1AHTR1B | |
| SCHEMBL17039301 | 0.72 | RXRA (0.55) | HDAC8PDE1APDE1BPDE1C | |
| SCHEMBL19701294 | 0.72 | PIK3CD (0.39) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023576-B2 | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170355698-A1 | HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023576-B2 | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | PIK3R3, PIK3R5, PIK3R1 | PIK3CD 6/4885HDAC8 1010/4885GPR119 1289/4885 |
| US-20170355698-A1 | HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS | PIK3R3, PIK3R5, PIK3R1 | PIK3CD 6/4885HDAC8 1010/4885GPR119 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.